14.95
+8.73%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enimmune
Its shares trade on Taipei Exchange under the ticker 6564.TWO. It has been listed since 18 September 2018. In the fiscal year to 31 December 2025, it reported revenue of TWD 48.2m and a net loss of TWD 164.3m. At that date it held total assets of TWD 456.1m and shareholders' equity of TWD 149.7m.
Enimmune Corp. engages in the research, development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-09-18. The firm's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The firm mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Sept 2018
- Website
- enimmune.com.tw ↗
Leadership
Pay as last reported
- Mr. Chung-Cheng LiuChairman of the Board, since 2014
- Hongdun ChenFinance Manager
- Mr. Zhewei ZhangGeneral Manager
- Mr. Simon KaoDeputy General Manager of Business-General Manager's Office
- Youkang LinHead of Accounting
- Jianrun ChenDirector
- Mr. Jin-Yi ChiouDirector
- Mr. Fei PanDirector
- Ms. Chia-Chi ChangIndependent Director
- Chongji LiIndependent Director
- Dawei MaIndependent Director
- Jiahui LiAssistant General Manager-Business Development Division, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enimmune Corp. develops innovative biotechnology products like Tuberculin PPD for global markets.
- The company focuses on drug research and development with a strong emphasis on biologics and vaccines.
- Enimmune Corp. operates in the Health Care sector with a clear focus on biotechnology innovation.
Weaknesses
- Enimmune Corp. is headquartered in Taipei City, Taiwan, which may limit its global market access.
- The company's business model relies heavily on drug testing and biotechnology services.
- Enimmune Corp. has limited product diversity beyond Tuberculin PPD and monoclonal antibodies.
Opportunities
- The global biotechnology market offers significant growth potential for Enimmune Corp.'s new drug products.
- Expanding into international markets could leverage Enimmune Corp.'s biotechnology services and drug development capabilities.
- The increasing demand for vaccines and monoclonal antibodies presents a key opportunity for Enimmune Corp.
Threats
- The biotechnology industry faces intense competition from established pharmaceutical companies.
- Regulatory challenges in drug development could delay Enimmune Corp.'s product launches.
- Economic downturns may reduce investment in biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.